CLBT — Cellebrite DI Ltd.

Cellebrite DI Ltd. Q4 and Full Year 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Annual Recurring Revenue (ARR): Grew 21% to $481 million, including $16.1 million from the Keryllium acquisition. Excluding Keryllium, ARR growth was 17%.
• Revenue: Q4 revenue increased 18% to $128.8 million; full-year revenue grew 19% to $475.7 million.
• Gross Profit: Q4 gross profit was $110.8 million, yielding a gross margin of 86%. Full-year gross margin was 85%.
• Adjusted EBITDA: Q4 adjusted EBITDA rose 33% to $38.3 million, with a margin of 29.8%. Full-year adjusted EBITDA totaled $127.6 million, representing a margin of 26.8%.
• Free Cash Flow: Generated $160 million for the year, achieving a free cash flow margin of 34%.
• Employee Count: Increased by 10% to 1,285 employees.

2. Strategic Updates and Business Highlights

• Product Innovations: Continued enhancements in digital forensics, particularly in mobile research and AI capabilities, with a focus on unlocking major phone manufacturers' devices.
• Acquisitions: Completed the acquisition of Keryllium, enhancing their technology portfolio. Announced plans to acquire SCG Canada, targeting the growing drone forensics market.
• SaaS and Cloud Adoption: SaaS offerings grew over 50%, now representing 22% of total ARR. The Guardian product line has seen consistent growth, with six consecutive quarters of over 100% year-on-year growth.
• Market Positioning: Positioned as a leader in digital forensics, with a focus on expanding capabilities across various data sources and enhancing AI integration.

3. Forward Guidance and Outlook

• 2026 Guidance: Initial ARR growth expected between 18% to 19%, with revenue growth projected between 19% to 20%. Anticipated adjusted EBITDA margin of 26% to 27%.
• Q1 2026 Expectations: ARR growth projected at $491 million to $493 million (20-21% growth), with revenue expected between $127 million to $129 million (18-20% growth).
• Growth Drivers: Anticipated contributions from new customer acquisitions, increased pricing, and expanded deployments of existing products.

4. Challenges and Points of Concern

• U.S. Federal Segment: Experienced headwinds in 2025, but management expects recovery in 2026, driven by pent-up demand and federal funding.
• Foreign Exchange Impact: Strengthening of the shekel against the dollar is expected to compress margins by about two points.
• Integration of Acquisitions: Concerns regarding the successful integration of Keryllium and SCG Canada while maintaining focus on core operations.

5. Notable Q&A Insights

• Acquisition Strategy: Management expressed confidence in managing multiple acquisitions concurrently, emphasizing the complementary nature of SCG Canada to their existing operations.
• Demand for Drone Forensics: Both customer demand and strategic foresight drove the decision to enter the drone forensics market, with expected significant growth potential.
• AI Developments: Management highlighted ongoing investments in AI to enhance product capabilities and improve user productivity, with plans to monetize AI applications in the near future.
• Federal Market Dynamics: The upcoming FIFA World Cup and increased funding for defense and intelligence are expected to drive demand in the U.S. federal segment.

Overall, Cellebrite DI Ltd. demonstrated solid financial performance in 2025, with strategic initiatives aimed at enhancing product offerings and expanding market reach, despite facing some challenges in the federal segment and foreign exchange impacts. The outlook for 2026 remains optimistic, with anticipated growth across various metrics.